Stryker Mako SmartRobotics: Robotic-arm system targets more precise joint replacement

Stryker's Mako SmartRobotics platform combines 3D CT-based planning with robotic-arm assistance to help surgeons perform more precise hip and knee replacements, and is now widely deployed in U.S. hospitals.

Responsible: ad hoc news Lifestyle & Consumer Desk. Reviewed prior to publication on June 12, 2026 at 10:10:18 PM ET. Details in the imprint.

Stryker's Mako SmartRobotics system is one of the most visible robotic-arm platforms in U.S. operating rooms for knee and hip replacement, pairing 3D CT-based planning with real-time intraoperative guidance. The system is designed to help orthopedic surgeons plan and execute bone cuts more accurately than with traditional manual instruments, with the goal of improving implant alignment and consistency. For patients, that can translate into a more personalized joint replacement plan, potentially smoother recovery, and greater confidence that a high-tech system supported the procedure.

How Mako SmartRobotics works in knee and hip replacement

Mako SmartRobotics is built around three core elements that Stryker highlights as CT-based planning, AccuStop haptic technology, and intraoperative data analytics, all integrated into a robotic-arm platform in the operating room. Before surgery, patients receive a CT scan of the joint, which is used to create a 3D model of the anatomy and to virtually position the implant based on the surgeon's choices for alignment, sizing, and soft-tissue balance. This planning phase allows the physician to see the bone structures and alignment in detail and to fine-tune the plan before a single cut is made in the operating room.

During surgery, the surgeon positions the robotic arm, which provides tactile boundaries through haptic feedback so that cutting and bone preparation remain within the virtual plan the physician created. If the surgeon's hand moves outside predefined boundaries, the haptic system limits the saw blade or burr, helping protect surrounding bone and soft tissue. The surgeon remains fully in control at all times, but the arm acts like a smart guide that can reduce variation and assist in maintaining the precise angles and depths that were defined in the pre-op plan. This combination of surgeon control and robotic constraint is what differentiates Mako from fully manual techniques that rely solely on mechanical jigs and the surgeon's experience.

Mako systems are configured to support multiple procedures, with dedicated workflows for total knee arthroplasty, partial knee resurfacing, and total hip arthroplasty using Stryker implants. For knees, the system can track ligament tension and joint line balance while bone is being prepared, giving the surgeon an opportunity to adjust implant positioning in real time based on how the joint behaves under motion. For hips, Mako provides guidance on acetabular cup positioning and leg length, aiming to reduce outliers in anteversion and inclination that can lead to dislocation or unequal leg length after surgery. This multi-indication approach allows hospitals to use a single robotic platform across a broad range of joint replacement cases.

Stryker reports that Mako SmartRobotics has been adopted globally and that procedure volumes have continued to grow as more hospitals add robotic-assisted programs and as surgeons become more familiar with the technology. In orthopedics, that adoption curve is important, because more installed systems and higher case volumes can support hospital marketing around technology-enabled joint programs and often attract patients who are actively searching for robotic options. Mako has become a central part of Stryker's orthopedic ecosystem, since it is designed to work with the company's Triathlon and other Stryker knee and hip implant families, tying the capital equipment to the ongoing consumable implant business.

Clinical data for Mako continues to be published in peer-reviewed journals, with results generally focusing on alignment accuracy, reduced outliers in component position, and functional outcomes compared with conventional techniques. Many centers report improvements in radiographic alignment metrics and high patient satisfaction, although the magnitude of benefit and the economic impact can vary between institutions. Robotic-assisted joint replacement typically involves a higher upfront capital investment, so hospitals often evaluate Mako not only on clinical outcomes but also on operating room efficiency, implant standardization, and the ability to drive higher case volumes through patient demand and referring-physician interest.

In the United States, Mako SmartRobotics is targeted at medium to large hospitals and dedicated orthopedic specialty centers that perform significant volumes of joint replacement and that are looking to differentiate their programs with advanced technology. Stryker offers the system as capital equipment with service and software support, and the company pairs the platform with staff training and surgeon education to help operating room teams integrate the technology into daily workflows. From a practical standpoint, surgeons who adopt Mako typically go through a learning curve that includes training labs and proctored cases, but once they are familiar with the workflow they can perform procedures within similar operating times as conventional methods, according to Stryker and multiple clinical reports.

From the patient's perspective, Mako is not a consumer product that can be purchased directly; instead, it is a hospital technology that shapes the care pathway when a person chooses a facility that offers robotic-arm assisted joint replacement. Patients researching hospitals in the U.S. often see references to Mako in marketing materials for orthopedic centers, where the platform is highlighted as a centerpiece of the joint program. For those considering surgery, typical questions to discuss with the surgeon include whether Mako is used for their specific indication, how the technology may affect implant choice and positioning, and what the surgeon's experience is with robotic-assisted versus conventional procedures.

For Stryker, Mako SmartRobotics has become a strategic cornerstone of its orthopedics and spine segment because it links capital sales, recurring instrument and implant revenue, and long-term hospital relationships across the joint replacement portfolio. Many analyst reports emphasize that record Mako adoption and strong procedure demand have been key growth drivers for the company in recent years. Shares of Stryker Corp. (US8636671013, ticker SYK) traded at $311.79 on NYSE on June 12, 2026.

Mako SmartRobotics at a glance

• Product: Mako SmartRobotics
• Manufacturer: Stryker Corp.
• Category: Lifestyle & Consumer - advanced medical technology impacting patient experience
• Launch date: Initial Mako robotic-arm knee system cleared in the U.S. in the 2000s, with expanded SmartRobotics platform introduced over the 2010s and 2020s
• MSRP / Price: Not publicly listed; capital equipment pricing typically negotiated individually between hospitals and Stryker in the U.S.
• Availability: Offered to U.S. hospitals and orthopedic centers through Stryker's sales organization; patients access the technology by choosing facilities that use Mako
• Target audience: Hospitals and surgical centers performing total knee, partial knee, and total hip replacements; indirectly adult patients with advanced knee or hip joint disease
• Key feature / USP: CT-based 3D planning combined with haptic-enabled robotic-arm guidance to help surgeons execute joint replacement plans with high precision

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.